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Abstract 
 
The microbes that collectively inhabit the gut - the gut microbiota - constitute the largest and 
most diverse community in the body. The gut microbiota is primarily responsible for the 
maintenance of the intestinal wall integrity and the protection against pathogens. These 
functions have long been attributed to the gut  microbiota  but  the  interest  of  the  scientific  
community  upon   this   collection  of microorganisms  began  to  emerge  when the first studies 
demonstrating its envelopment in obesity were published. 
Besides having an important role in the regulation of host energy metabolism, the gut 
microbiota can also influence neurodevelopment, modulate behavior and contribute to the 
development of neurological disorders. Thus, the gut microbiota might constitute a potential 
target for the treatment of obesity and the associated neuropsychiatry disorders.  
Anthocyanins are a particular class of flavonoids that can be found mainly in red wine and red 
fruits. Anthocyanins bioavailability is considered to be low but it remains to be properly 
addressed. In addition, when they reach the colon they can be metabolized by the gut 
microbiota and may modulate bacterial growth. Whether gut microbiota modifications are 
responsible for the neuropreotective effects of anthocyanins remains unknown. 
Using a Rat model of diet-induced obesity, the effects of blackberry anthocyanins upon gut 
microbiota composition were evaluated in the present thesis. Results from this work strongly 
suggest that dietary manipulation of the gut microbiota by anthocyanins can attenuate the 
neurologic complications of obesity, expanding the classification of psychobiotics to 
anthocyanins. 
Regarding their bioavailability, the clinical trial conducted in the current thesis indicate that 
anthocyanins are extensively metabolized after absorption. Furthermore, it showed, for the first 
time, that ethanol enhances cyanidin metabolism, potentiating its conversion into methylated 
derivatives, especially in overweight and obese individuals.  
These results should prompt the attention of the scientific community to the fact that the kinetic 
of these compounds is influenced by body composition and deserve special considerations since 
obese individuals might be the ones who would benefit the most from anthocyanins 
intervention. 
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This thesis brought new insights on anthocyanins bioavailability and have clarified the 
mechanisms by which anthocyanins participate in the bilateral communication between gut and 
brain. Future clinical interventional studies are warranted to validate these findings. 
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Resumo 
 
Os microrganismos que habitam coletivamente o intestino - o microbiota intestinal - constituem 
a comunidade mais densa e mais diversa do corpo humano. O microbiota intestinal é 
principalmente responsável pela manutenção da integridade da barreira intestinal e pela 
proteção contra agentes patogénicos. Há muito que estas funções do microbiota intestinal são 
conhecidas, mas o interesse da comunidade científica sobre esta coleção de microrganismos 
começou a emergir quando foram publicados os primeiros estudos que demonstram seu 
envolvimento na obesidade.  
Além de ter um papel importante na regulação do metabolismo energético do hospedeiro, o 
microbiota intestinal pode também influenciar o neurodesenvolvimento, modular o 
comportamento e contribuir para o desenvolvimento de perturbações neurológicas. Assim, o 
microbiota intestinal poderá constituir um potencial alvo para o tratamento da obesidade e das 
perturbações neuropsiquiátricas associadas à obesidade. 
As antocianinas são uma classe particular de flavonoides, encontrando-se principalmente no 
vinho tinto e nos frutos vermelhos. A biodisponibilidade das antocianinas é considerada baixa, 
porém esta nunca foi devidamente avaliada. Além disso, quando atingem o colon, podem ser 
metabolizadas pelo microbiota intestinal e modular o crescimento bacteriano. No entanto, 
permanece por esclarecer se as modificações do microbiota intestinal são responsáveis pelos 
efeitos neuroprotetores das antocianinas. 
Usando um modelo animal de obesidade induzida pela dieta, os efeitos das antocianinas 
presentes na amora sobre a composição do microbiota intestinal, foram avaliados nesta tese. Os 
resultados deste trabalho sugeriram fortemente que a manipulação do microbiota intestinal 
com antocianinas pode atenuar as complicações neurológicas da obesidade, alargando a 
classificação de psicobióticos às antocianinas.  
Em relação à sua biodisponibilidade, o ensaio clínico conduzido nesta tese, revelou que as 
antocianinas, depois de absorvidas, são extensamente metabolizadas. Para além disso, revelou, 
pela primeira vez, que o etanol estimula o metabolismo da cianidina, potenciando a sua 
conversão em derivados metilados, especialmente em indivíduos com excesso de peso ou 
obesidade.  
Estes resultados devem chamar a atenção da comunidade científica para o facto da cinética 
desses compostos ser influenciada pela composição corporal e merecem considerações 
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particulares uma vez que os indivíduos pré-obesos ou obesos são aqueles que mais beneficiarão 
da intervenção com antocianinas. 
Esta tese trouxe novas considerações sobre a biodisponibilidade das antocianinas e clarificou os 
mecanismos pelos quais as antocianinas participam na comunicação bilateral entre o intestino e 
o cérebro. Estudos clínicos de intervenção são necessarios para a validação destes resultados  
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Introduction 
 
The human body harbors a collection of trillions of microorganisms. Bacteria, archaea, virus 
fungi and other eukaryotes live inside different organs establishing a symbiotic relationship with 
the host [1-3]. The microbes that collectively inhabit the gut - the gut microbiota - constitute the 
largest and most diverse community in the body [4]. Most of them are bacteria belonging to the 
Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria or Verrucomicrobia phylum (Table 1) 
[5].  
 
Table 1 - Phylogenetic classification of the most abundant bacteria in the gut.  
 
Phylum Class Order Family Genus 
Firmicutes 
Clostridia Clostridiales 
Lachnospiraceae 
Lachnoclostridium 
Roseburia 
Acetatifactor 
Ruminococcaceae 
Ruminococcus 
Ruminiclostridium 
Sporobacter 
Unclassified 
Intestinimonas 
Flavonifractor 
Pseudoflavonifractor 
Eubacteriaceae Eubacterium 
Clostridiaceae 
Hungatella 
Clostridium 
Oscillospiraceae Oscillibacter 
Bacilli Lactobacillales 
Lactobacillaceae Lactobacillus 
Enterococcaceae Enterococcus 
Bacteroidetes Bacteroidia Bacteroidales 
Bacteroidaceae Bacteroides 
Prevotellaceae Prevotella 
Actinobacteria Actinobacteria Bifidobacteriales Bifidobacteriaceae Bifidobacterium 
Proteobacteria Deltaproteobacteria Desulfovibrionales Desulfovibrionaceae Desulfovibrio 
Verrucomicrobia Verrucomicrobiae Verrucomicrobiales Akkermansiaceae Akkermansia 
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The gut microbiota is primarily responsible for the maintenance of the intestinal wall integrity 
and the protection against pathogens. The bacterial fermentation of non-digestible 
carbohydrates leads to the formation of short chain fatty acids (SCFA) which reduces luminal pH 
and inhibits the growth of pathogens [6, 7]. On the other hand, butyrate, one of the most 
abundant SCFA in the gut, regulates epithelial cell growth and differentiation, thus contributing 
to the intestinal barrier reinforcement [8-10]. Besides, the gut microbiota can synthesize certain 
vitamins, such as vitamin K and B group vitamins including biotin, cobalamin, folates, nicotinic 
acid, pantothenic acid, pyridoxine, riboflavin and thiamine [11]. Furthermore, it is involved in the 
bile acids transformation as some bacteria have the ability to hydrolyze the amide bond 
between the steroid nucleus and the conjugated amino acid (taurine or glycine) [12]. In addition 
to bile acid deconjugation, some bacteria can then convert the primary bile acids into secondary 
bile acids through 7α-dehydroxylation or 7α-dehydrogenation, thus increasing the diversity of 
the bile acid pool [12].  
These structural, protective and metabolic functions have long been attributed to the gut  
microbiota  but  the  interest  of  the  scientific  community  upon   this   collection  of 
microorganisms  began  to  emerge  when the first studies demonstrating its envelopment in 
obesity were published [13, 14].  
The gut microbiota in the etiology of obesity  
Obesity is defined by the World Health Organization (WHO) as an excessive fat accumulation 
that presents a risk to health [15]. The etiology of obesity is multifactorial but, in ultimate 
analysis, it results from an energy imbalance in favor of body energy input. Current estimates are 
that 70.7% of US adults (above 20 years old) are either overweight or obese, with approximately 
38% obese [16]. In Portugal, 36.5% of the adult population (18-64 years old) reveals pre-obesity 
while 21.6% are obese [17]. However, the main cause of concern is not obesity itself but rather 
the comorbidities associated with it. Overweight (30 > body mass index (BMI) ≥ 25 kg/m2) and 
obese people (BMI ≥ 30 kg/m2) are at increased risk for many chronic diseases such as type 2 
diabetes, cardiovascular diseases (the major cause of global mortality) and certain types of 
cancer [18-20]. Besides, obesity undeniably increases the risk of mental illness such as clinical 
depression, anxiety and other mental disorders [21, 22].  
As genetic and environmental factors failed to solely explain the magnitude of obesity epidemic, 
new hypotheses emerged to explain the etiopathogenesis of this condition [23].  
In 2004, little attention was being paid to the gut microbiota when it appeared to be a factor 
affecting predisposition towards obesity [13]. Using germ-free mice (mice raised without any 
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exposure to microorganisms), Backhed et al found that mice lacking microbiota had about 40% 
less total body fat than conventionally raised mice [13]. In addition, the authors found that 
colonizing germ-free animals with gut microbiota from conventionally raised mice resulted in 
60% increase of body fat mass, in only two weeks [13]. 
In 2006, Turnbaugh et al demonstrated that the gut microbiota of genetically obese mice 
differed from their lean littermates in the relative abundance of Firmicutes and Bacteroidetes 
[14]. Similar results were obtained when the authors compared the gut microbiota of lean and 
obese human volunteers [24]. Moreover, Turnbaugh et al revealed that obesity could be 
transmitted to germ-free mice if these animals were colonized with an ‘obese’ microbiota [25].  
These pioneering findings have established a causal relationship between gut microbiota and 
obesity and have encouraged subsequent research. Thenceforward, due to the development of 
culture-independent techniques and omics-based approaches (metagenomics, 
metatranscriptomics and metabolomics), which facilitated not only the identification and 
classification of the microorganisms existing in the gut but also the assessment of their encoded 
genes (microbiome) and gene products; the number of publications regarding the gut microbiota 
has increased exponentially: while ten years ago a search for “gut microbiome” in PubMed 
would retrieve 9 results, now more than 2 000 papers are published per year.  
Mechanisms linking gut microbiota to obesity 
The gut microbiota plays an important role in the regulation of host energy metabolism [26-32]. 
The initial studies, conducted in germ-free and conventionally raised mice, demonstrated that 
the gut microbiota can influence both sides of the energy balance equation (energy input and 
energy expenditure) by increasing energy harvest from components of the diet and by affecting 
host genes that regulate how energy is expended and stored (Figure 1) [25, 33].  
In a nutshell, dietary polysaccharides that escape digestion in the upper part of the 
gastrointestinal tract are utilized by the gut microbiota when they reach the colon. Gut bacteria 
provide glycoside hydrolases and polysaccharide lyases required to cleave glycosidic linkages in 
plant glycans [34, 35]. The resulting monosaccharides are either absorbed (the gut microbiota 
increases monosaccharide uptake from the gut [13] and facilitates their delivery to the portal 
circulation [36]) or metabolized into SCFA (mainly acetate, propionate and butyrate). Both are 
substrates for de novo lipogenesis in the liver [37]. Accordingly, the gut microbiota increases the 
expression of key transcriptional factors in the liver, carbohydrate response element binding 
protein (ChREBP) and sterol response element binding protein 1 (SREBP-1), that enhance de 
novo lipogenesis (Figure 1) [13].  
 CHAPTER I 
 
  - 12 - 
The newly synthesized lipids are then deposited in adipocytes through a process that involves, in 
part, microbial suppression of the intestinal production of fasting-induced adipose factor (FIAF), 
a secreted lipoprotein lipase (LPL) inhibitor [13, 38]. Thus, increased hepatic lipogenesis is 
coordinated with increased LPL activity, to promote storage of the additional energy harvested 
in adipocytes (Figure 1).  
On the other side of the balance equation, the gut microbiota suppresses adenosine 
monophosphate-activated protein kinase (AMPK) activity, the fuel gauge of eukaryotic cells. 
Inhibition of AMPK results in reduced muscle and liver fatty acid oxidation leading to the 
accumulation of the excess fatty acids in these tissues (Figure 1) [33].  
 
Figure 1 - Functional alterations of the gut microbiota in obesity (on the left). Proposed 
mechanisms by which gut microbiota regulates host energy metabolism and influences 
metabolic processes in peripheral organs (on the right). Adapted from Tremaroli et al [39]. 
AMPK, adenosine monophosphate-activated protein kinase; ChREBP, carbohydrate response 
element binding protein; eCB, endocannabinoid; FIAF, fasting-induced adipose factor; GLP-1, 
glucagon-like peptide-1; LPS, lipopolysaccharide; LPL, lipoprotein lipase; PYY, peptide YY; SCFA, 
short-chain fatty acids; SREBP-1, sterol response element binding protein 1; TG, triacylglicerides.  
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Genetically obese mice and obese individuals have an increased capacity to extract energy from 
food as their microbiome exhibit an overexpression of genes encoding enzymes able to digest 
complex plant-derived polysaccharides [25, 40]. As a result, they also present higher amounts of 
fecal SCFA [25, 41, 42]. Nevertheless, contrasting evidence has shown that SCFA interventions 
[43-48] as well as dietary interventions with nondigestable carbohydrates may have beneficial 
effects in the prevention of obesity [49-52]. SCFA can directly regulate host energy metabolism 
in peripheral tissues by binding to G-protein-coupled receptors (GPR41, also known as FFAR3 
and GPR43, also known as FFAR2) found in colonic tissue, adipose tissue, muscle, liver and brain 
[53-58]. E.g. SCFA increase energy expenditure, stimulate the production of gut-derived satiety 
hormones PYY and GLP-1 by L-cells and enhance central appetite regulation [46, 47, 59-62]. 
Thus, despite the production of SCFA could be altered in obesity (including SCFA profile), the 
relevance of energy harvest from nondigestable carbohydrates is still debated. In the meantime, 
other mechanisms linking gut microbiota to obesity have been proposed.  
In 2007, Cani et al presented lipopolysaccharide (LPS) as a triggering factor of obesity and 
metabolic diseases [63]. LPS is a component of gram-negative bacteria (prevailing in our gut) 
that can activate an extensive inflammatory cell signaling pathway when it binds to toll-like 
receptor 4 (TLR4) [64]. Crossing the intestinal barrier via a paracellular or a transcellular route 
[65], LPS may reach the systemic circulation at concentrations five times lower than those 
observed in sepsis, inducing a state denominated as ‘metabolic endotoxemia’ [63, 66]. In their 
work, the authors were successful in demonstrating that LPS infusions in chow-fed mice induce a 
metabolic response similar to high-fat (HF) diet feeding (increased body weight gain and 
adiposity) [63]. 
On the other hand, both ob/ob and diet-induced obesity mice display higher circulating levels of 
LPS than respective control mice, which is consistent with the increased gut permeability 
observed in these animals [66, 67]. Similarly, obese individuals [68], with type 2 diabetes [69-72] 
or non-alcoholic fatty liver disease (NAFLD) [73] also reveal elevated LPS levels. 
LPS may be transported from the intestine towards target tissues through the newly synthesized 
chylomicrons in response to fat feeding [74-76]. Once in circulation, LPS may activate CD14/TLR4 
signaling in adipose tissue [69], muscle [77], liver [78] and brain [79, 80]. These data support the 
hypothesis that LPS is involved in the onset of the low-grade inflammatory status that 
characterizes obesity and insulin resistance [81].  
Among the putative mechanisms linking the gut microbiota to obesity, a role for the 
endocannabinoid system has also been proposed, probably involving LPS and its influence on 
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cannabinoid receptors signaling [82-85]. Activation of the endocannabinoid (eCB) system in the 
intestine (e.g. by the gut microbiota) increases gut permeability, which enhances LPS levels and, 
consequently, eCB system tone in peripheral tissues [85]. Increased eCB system tone in adipose 
tissue stimulates adipogenesis and promotes adipose tissue expansion [86]. Therefore, the 
crosstalk between gut microbiota and adipose tissue may be mediated by the eCB system. 
During the last decade, bile acids have emerged as novel metabolic modulators. The major 
function of bile acids is to facilitate the emulsification of dietary fats and to aid the intestinal 
absorption of lipids and lipophilic vitamins [12]. Nevertheless, recent evidence have shown that 
bile acids represent signaling molecules in the host with the capacity to regulate cellular and 
metabolic activities by activating the farnesoid-X-receptor (FXR), the vitamin D receptor (VDR) or 
the G protein-coupled bile acid receptor TGR5 [87-89]. E.g. TGR5 signaling in enteroendocrine L-
cells induces secretion of GLP-1, thereby enhancing glucose tolerance [88]. Since different 
receptors have different affinities for individual bile acids, subtle variations in the bile acid 
signature may alter the signaling properties of the bile acid pool with a subsequent impact on 
host physiology [12]. These variations are likely to occur whenever gut microbiota is perturbed. 
In diet-induced obesity models, higher amounts of bile acids are released into the small intestine 
in response to the fat content of the diet [90]. Given their amphipathic properties, bile acids may 
damage bacterial cell membranes as well as host cell membranes by interacting with membrane 
phospholipids [91]. Therefore, in addition to their role in lipid and glucose metabolism, bile acids 
may contribute to explain the gut microbiota alterations and the increased gut permeability 
associated to obesity [92-94]. 
In summary, the gut microbiota is an important organ involved in the maintenance of host 
energy homeostasis by means of a molecular crosstalk. Thus, the gut microbiota as well as gut 
microbial metabolites constitute potential targets for the treatment of obesity and metabolic 
disorders such as, type 2 diabetes, cardiovascular diseases and NAFLD. In this regard, the 
identification of robust biomarkers, on the basis of gut microbiota, for the early diagnosis of 
obesity related metabolic diseases is warranted.  
The microbiota-gut-brain axis 
Besides having an important role in the regulation of host energy metabolism, the gut 
microbiota can also influence neurodevelopment, modulate behavior and contribute to the 
development of neurological disorders [95-100]. Resembling obesity, behavioral phenotypes can 
be transmitted to germ-free mice after gut microbiota transplantation [101]. 
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The microbiota-gut-brain axis encompasses the strong bidirectional communication between the 
gut microbiota and the central nervous system (CNS) [102]. Multiple mechanisms may be 
involved in this bilateral communication, including immune (cytokines), endocrine (cortisol) and 
neural (vagus and enteric nervous system) pathways (Figure 2). However, while the effects of 
the autonomic nervous system on gut physiology have long been understood, the effects of gut 
microbiota on CNS physiology are still being unraveled. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 - Pathways involved in the bidirectional communication between gut microbiota and 
brain; the microbiota-gut-brain axis. Adapted from Cryan et al [103]. HPA, hypothalamic-
pituitary-adrenal; SCFA, short-chain fatty acids. 
Gut microbial metabolites such as SCFA are signaling molecules in the host, as described in the 
previous section. Nonetheless, SCFA have not only a significant role in the regulation of satiety, 
but also exhibit different neuroactive properties [99, 104, 105]. Besides, gut bacteria have the 
capacity to produce many neurotransmitters and neuromodulators such as gamma-
aminobutyric acid (GABA), noradrenaline, serotonin and acetylcholine (Figure 2) [106, 107]. In 
addition, it has the ability to control host tryptophan metabolism, regulating the fraction of 
tryptophan available for serotonin synthesis and, on the other hand, the production of 
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neuroactive and neurotoxic metabolites [108-110]. Lastly, the gut microbiota can induce the 
secretion of neurotrophic factors by intestinal smooth muscle cells such as the brain-derived 
neurotrophic factor (BDNF), an important plasticity-related protein that promotes neuronal 
growth, development and survival [111]. Therefore, the gut microbiota can communicate with 
the brain by several mechanisms and may be implicated in the development of many neurologic 
conditions. 
One of the key players in the development of neuropsychiatric comorbidities in obesity is the 
inflammatory process [112]. Inflammation can be originated in the gut, since gut microbiota 
alterations in obesity may increase intestinal permeability and, consequently, LPS circulating 
levels, leading to the development of chronic low-grade endotoxemia. The increased production 
of proinflammatory cytokines (e.g. interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis 
factor-α (TNF-α)) by immune cells may, ultimately, activate microglia within CNS. Nevertheless, 
while microglia activation normally exerts a protective action on the CNS, its unregulated and 
chronic activation may, in contrast, become deleterious, causing significant alterations in CNS 
functions (e.g. changes in neuroendocrine function, neurocircuitry, enzymatic pathways, and 
neurotransmitter metabolism/function) [113]. Thus, the gut microbiota can be viewed as a key 
triggering factor of inflammation-driven neuropsychiatric comorbidities. For that reason, 
modulation of the gut microbiota might be a tractable strategy to the development of novel 
therapeutics for complex CNS disorders, including those associated with obesity. 
Modulation of gut microbiota by dietary factors  
Diet is an important factor that can rapidly induce changes in gut microbiota composition [114-
117]. Gut microbiota modifications in response to dietary changes may occur within 24-48 h 
[115]. These fast and diet-induced dynamics are supported by studies in which participants 
switched between plant- and meat-based diets. Animal-based diets increased the abundance of 
bile-tolerant bacteria (Alistipes, Bilophila and Bacteroides) while plant-based diets increased the 
levels of bacteria belonging to the Firmicutes phylum that have the ability to metabolize plant 
polysaccharides (Roseburia, Eubacterium rectale and Ruminococcus bromii) [115]. These dietary 
shifts alter the nutrients available for gut bacteria, favoring the growth of specific species, thus 
resulting in modifications in gut microbiota composition. Nevertheless, long-term dietary habits 
are a dominant force in determining the gut microbiota composition of an individual [118]. 
Despite the gut microbiota composition can detectably change within 24 h, enterotype identities 
may remain stable even after 10-day dietary interventions [5, 119].  
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On the other hand, this ‘hidden’ metabolic organ, as it is commonly referred, has also an 
important role in arbitrating the impact of dietary interventions on host metabolism. I.e., the 
effects of dietary interventions on host metabolic parameters may rely on the gut microbiota 
composition. For instance, dietary interventions with complex carbohydrates may increase 
microbiota diversity and the metabolic output (SCFA), but only if individuals have a diverse 
microbiota at baseline [120]. When the diversity of the gut microbiota is low, residual bacteria 
will not be able to handle all the complex carbohydrates available from the diet and the diversity 
of the ecosystem will probably remain low [118].  
The gut microbiota plays therefore an important role at the intersection of diet and health. The 
resistance to ecological stress and the ability to recover from a stress-related perturbation 
(resilience) are the characteristics of a healthy microbiota that empowers its maintenance 
throughout life [121]. When the microbial ecosystem is perturbed to an extent that exceeds its 
resistance and resilience capabilities, alterations in its composition and function may occur 
(dysbiosis) [122].  
 
 
  
 
 
 
 
 
 
Figure 3 - Adapted from Round et al. [123] Dysbiosis typically features one or more of the 
following non-mutually exclusive characteristics: (i) loss of beneficial microbial organisms, (ii) 
expansion of pathobionts or potentially harmful microorganisms and (iii) loss of overall microbial 
diversity (both in terms of richness and evenness). Beyond diet, other factors may influence the 
composition of the intestinal microbial community. Xenobiotics such as antibiotics have the 
potential to dramatically alter the homeostatic commensal colonization [124-126]. Infection and 
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inflammation can also compromise the microbiota’s ability to provide colonization resistance 
against invading microorganisms [127, 128]. In addition, genetic background is a stronger 
determinant of the gut microbiota composition [129, 130]. 
The expansion of pathobionts (commensal microorganisms that can cause pathology under 
uncontrolled proliferation), the loss of beneficial bacteria and the loss of diversity (microbial 
richness) are common characteristics of a dysbiotic state (Figure 3) [122, 131].  These features 
have detrimental consequences for the host (may initiate obesity and metabolic diseases as well 
as neurologic disorders) and can be caused by environmental factors such as dietary 
modifications that encompass high contents of fat. Other factors have been suggested as 
potential instigators of dysbiosis such as non-caloric artificial sweeteners [132, 133] and dietary 
emulsifiers [134, 135].   
Anthocyanidins, a particular class of flavonoids  
Polyphenols are phytochemicals that result from the secondary metabolism of plants. These 
chemicals are not essential for the immediate survival of plants but increase their chances to 
survival in hostile environments. They are important to plant defense mechanisms, propagation 
and development and contribute to their colors, aroma, flavor, bitterness and astringency [136]. 
Structurally, flavonoids are polyphenols characterized by a flavan nucleus which consists in a C6-
C3-C6 structure [137]. Flavonoids are divided into 14 different classes. The level of oxidation and 
the pattern of substitution at the C ring dictate the class to which flavonoids belong [137, 138].  
 
 
 
 
 
Figure 4 - Representation of the general structure of anthocyanidins (flavylium form). These 
compounds differ in the methoxyl and hydroxyl substitution pattern of the aromatic B ring.  
Anthocyanidins are a particular class of flavonoids. Attending to their chemical nature, 
anthocyanins naturally occur as glycosides of flavylium (2-phenylbenzopyrylium) salts and are 
commonly based on six anthocyanidins: pelargonidin, cyanidin, delphinidin, petunidin and 
malvidin (Figure 4). The sugar moieties vary but are usually glucose, rhamnose, galactose or 
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arabinose. The most widespread anthocyanins are glycosylated in the 3-OH position (3-O-
monoglycosides) [139].  
These compounds are naturally part of our diet as they can be found mainly in red wine and red 
fruits such as cherries, strawberries, plums, blackberries, raspberries, grapes, red currants and 
black currants but also in some cereals and root vegetables (e.g. aubergines, beans, cabbage, 
radishes and onions) [140].  
The bioavailability of anthocyanins, i.e. the percentage of anthocyanins that reach the 
bloodstream after an administered dose, is considered to be low. Nevertheless, this might be 
attributed to several major drawbacks or limitations of the current studies [141]. In fact, the 
bioavailability of anthocyanins is the most difficult to assess amongst all flavonoids as a result of 
their occurrence under  different  structures depending on pH [142]. 
The analysis of anthocyanins and their metabolites in biological samples (plasma, urine and 
feces) requires important steps such as sample preparation and purification, which are decisive 
for an accurate estimation of anthocyanins bioavailability. Nonetheless, the analytical detection 
of anthocyanins and anthocyanin metabolites in biological samples is not an easy task since it 
requires the appropriate analytic standards that are not commercially available and have to be 
chemically synthetized. For that reason, the majority of studies have only looked for the parent 
structure of anthocyanins, underestimating the total anthocyanins content that might actually 
reach the target organs [143]. Besides, anthocyanins bioavailability might also be strongly 
influenced by the food matrix. In red wine, anthocyanins are consumed concomitantly with 
ethanol but it remains unclear whether ethanol enhances anthocyanins bioavailability.  
Despite all these issues, anthocyanins are particularly interesting since those that are not 
absorbed in the small intestine might be metabolized by the gut microbiota when reaching the 
colon [144]. Microbial metabolism of anthocyanins may alter the bioactivity of these compounds 
but, on the other hand, may modulate bacterial growth. Only a few studies have analyzed the 
effect of anthocyanins on gut microbiota modulation and it remains unclear whether they can be 
used as prebiotics [145-147]. 
Moreover, anthocyanins have emerged as anti-inflammatory agents and are promising 
candidates for the prevention of neuroinflammation, a common hallmark of obesity-associated 
neuropsychiatry disorders [148-151]. The mechanisms underlying these effects might be related 
to the interaction of anthocyanins with neuron and microglia biology. Recent studies suggest 
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that anthocyanins may protect neurons against neuroinflammatory injury by stimulating the 
production of proteins involved in synaptic plasticity [148, 152].  
Anthocyanins and their metabolites are able to cross the blood-brain barrier [153]. Nonetheless, 
to be neuroprotective, anthocyanins do not necessarily need to reach the brain. By changing the 
gut microbiota and acting on the gut-brain axis, anthocyanins may exert a biological activity even 
without being absorbed. However, whether the anti-neuroinflammatory properties of 
anthocyanins are related to the gut microbiota changes that these compounds might bring 
about remains to be unraveled. 
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Aims 
 
The general aim of this investigation was to unravel the effects of anthocyanins on gut 
microbiota, a metabolic organ that can communicate with the brain and might be implicated in 
obesity related neuropsychiatry disorders. Additionally, this study aimed to clarify the 
bioavailability of anthocyanins.  
  
The specific aims, related to our different approaches, were the following: 
  
Chapter II 
 
- To compare the metabolic and gut microbiota alterations driven by HF diet, in two Rat models 
of diet-induced obesity; 
 
- To track potential plasma markers of intestinal inflammation and permeability as well as gut 
microbiota dysbiosis, in the most suitable Rat model of HF diet-induced obesity; 
 
- To highlight HF diet-induced dysbiosis as a likely cause of neuroinflammation; 
 
- To investigate whether blackberry anthocyanins can counteract HF-diet induced dysbiosis and 
whether gut microbiota modulation is behind the neuroprotective effects of anthocyanins. 
 
Chapter III 
 
- To evaluate the bioavailability of anthocyanins after blackberries consumption and the effect of 
ethanol on the bioavailability of these compounds. 
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TARGETING GUT-BRAIN AXIS WITH ANTHOCYANINS: A NEW CLASS OF PSYCHOBIOTICS 
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Background Anthocyanins, a particular class of flavonoids found in berries, are able to control 
neuroinflammation in high-fat (HF)-diet induced obesity models. On the other hand, anthocyanins are 
subjected to gut microbiota metabolism and may modulate bacterial growth. The goal of this work was 
to test the hypotheses: 1- Anthocyanins can modulate gut microbiota composition and counteract HF-
diet induced dysbiosis; 2- Modifications in gut microbial environment may be involved in the anti-
neuroinflammatory properties of anthocyanins.  
Methods Wistar rats were randomly divided into 4 groups (n=6 per group): (C) standard diet; (C+BE) 
standard diet + blackberry anthocyanin rich extract; (HF) high-fat diet; (HF+BE) high-fat diet + blackberry 
anthocyanin rich extract. BE was supplied daily in food (25 mg/kg body weight). After 17 weeks, the 
animals’ gut microbiota composition was evaluated by sequencing 16S rRNA gene. Fecal and urine 
metabolome was analyzed by HPLC/Orbitrap. These outcomes were then correlated with the 
neuroinflammatory markers previously measured in the hippocampus of these animals.  
Results BE counteracted some of the features of HF-diet induced dysbiosis. Pseudoflavonifractor and 
Sporobacter (bacterial genus increased by BE in C and HF diets, respectively) were negatively correlated 
with thymus chemokine-1 (TCK-1), a potent chemoattractant which expression is decreased in the 
hippocampus of animals supplemented with BE.  In addition, BE altered host tryptophan metabolism 
increasing the production of the neuroprotective metabolite kynurenic acid, possible responsible for the 
effects of BE on neuroinflammation.  
Conclusions Our results demonstrate that anthocyanins may counteract the HF diet-induced 
neuroinflammation through gut microbiota modulation, thereby acting on the bilateral communication 
between gut and brain. 
 
Keywords: Anthocyanins; Gut-brain axis; Microbiota; Neuroinflammation; Obesity; Tryptophan 
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INTRODUCTION 
 
The incidence of neurodegenerative diseases, 
such as Alzheimer's and Parkinson's diseases 
has been increasing as global population gets 
older. The World Health Organization (WHO) 
predicts that by 2040, neurodegenerative 
diseases will overtake cancer to become the 
second leading cause of death after 
cardiovascular disease [141]. Accumulating 
evidence suggests that neurodegeneration 
occurs, in part, because neurons' environment 
is disturbed in a cascade of processes 
collectively called neuroinflammation [142]. 
Neuroinflammation is also central in other 
psychiatry disorders such as anxiety and 
depression which are often associated with 
obesity [143, 144]. Neuroinflammatory 
processes are profoundly modulated by 
peripheral inflammatory stimuli, especially 
those coming from the gut microbiota [145-
147]. In this regard, both central nervous 
system (CNS) and gut microbiota offer 
legitimate targets for novel therapeutic 
strategies aiming to treat the rising burden of 
neuropsychiatry disorders. 
Flavonoids are a class of polyphenolic 
compounds that have been pointed as key 
elements in the treatment of 
neurodegenerative diseases [148]. Undeniably, 
anthocyanins (often consumed in higher 
amounts than other flavonoids [149]) do 
interact with neurons and microglia biology, 
facilitating synaptic connectivity under both 
regular and pathologic conditions [150]. In 
addition, as recently demonstrated, 
anthocyanins are able to attenuate the 
negative impact of high-fat (HF) diets on 
neuroinflammation [151]. On the other hand, 
anthocyanins may also exert their effects 
through gut microbiota modulation [137].  
The aim of the present study was to test the 
hypothesis that anthocyanins modulate gut 
microbiota composition and prevent HF diet-
induced dysbiosis. After confirming these 
assumptions and given the bilateral 
connectivity that exists between gut and brain 
(the gut-brain axis) [152, 153], we went further 
to investigate whether gut microbiota 
modulation was behind the previously 
observed effects of anthocyanins on 
neuroinflammation.  
 
METHODS AND MATERIALS 
 
Animals 
Twenty-four male Wistar rats were randomly 
divided into four groups (n=6 per group), as 
previously described: (C) standard diet; (C+BE) 
standard diet + blackberry anthocyanin rich 
extract; (HF) high-fat diet; (HF+BE) high-fat diet 
+ blackberry anthocyanin rich extract [151, 
154]. Animals were fed ad libitum with 
“standard” (Teklad 2014, Harlan Laboratories, 
Santiga, Spain) or “high-fat” diets (D1245 
Research Diets, New Brunswick, USA) for 17 
weeks. Blackberry anthocyanin rich extract (BE, 
25 mg/kg body weight/day) was obtained as 
previously described [151]. BE was dissolved 
daily in sterile water and embedded in food 
pellets that animals had daily access to. Animal 
handling and housing protocols followed 
European Union guidelines (86/609/EEC) for 
the use of experimental animals. The study 
obtained ethical approval from the Ethical 
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Committee of the Faculty of Medicine of 
University of Porto. 
 
DNA extraction from stool and 16S rRNA 
sequence analysis 
Fresh fecal samples were collected directly 
from the colon of all animals, snap-frozen in 
liquid nitrogen and stored at -80 °C until further 
analysis. Genomic DNA was extracted and 
purified from stool samples using NZY Tissue 
gDNA Isolation Kit (NZYTech, Lisbon, Portugal) 
as previously described by Marques et al. [155].  
Libraries were prepared following the 16S 
Metagenomic Sequencing Library Preparation 
protocol from illumina (illumina; San Diego, CA, 
USA).  The region of interest was captured 
using the Klidnworth et al. set of primers that 
covered the hypervariable region V3-V4 of the 
bacterial 16s rRNA [156]. Samples were pooled 
and loaded into the illumina MiSeq System and, 
then, sequenced using a 300PE combination 
according to manufacturer’s specifications. 
Raw sequencing reads were merged with PEAR 
v0.9.6. Amplification primers were trimmed 
from the sequences obtained using the default 
program settings of cutadapt v1.9.1 [157]. 
Sequencing quality filtering was subsequently 
applied to isolate the sequences having more 
than 300 nts with a mean quality score ≥ 20. 
Sequences were excluded from all downstream 
analyses. Sequences were also inspected for 
PCR chimera constructs. The resulting sequence 
reads were clustered into operational 
taxonomic units (OTU) at 98% similarity, using 
cd-hit program. NCBI database was used to 
assign a taxonomic classification to each read in 
the representative set. Reads with no hits in the 
reference sequence collection were classified 
as “null”. OTUs with a relative abundance < 1% 
in all samples were considered non-significant 
and are not presented. Shannon’s richness 
index was calculated using the formula 
described in [158]. 
 
Neuroinflammation assessment 
As previously described, neuroinflammatory 
markers were measured in the hippocampus of 
all animals using a predefined cytokine glass-
based array (Quantibody Rat Cytokine Array; 
RayBiotech), according to manufacturer’s 
instructions [151].  
 
Fecal LPS quantification  
Quantification of LPS was performed using the 
Chromo-Limulus Amebocyte Lysate (Chromo-
LAL) reagent (Associates of Cape Cod, Inc., 
Falmouth, MA, USA). Briefly, 1 mL of sterile 
saline solution (NaCl 0.9 %) was added to 100 
mg feces, vortexed and centrifuged (10 min, 
10000 g, 4 °C) twice. Total supernatant (fecal 
water) was filtered with 0.45 μm filter and then 
with 0.22 μm filter. Fecal water and Chromo-
LAL (1:1) were incubated at 37 °C for 20 min 
and absorbance was read every 10 s at 405 nm. 
 
Fecal and urine metabolome analysis by 
HPLC/Orbitrap 
The fecal water obtained for LPS quantification 
was also used for metabolomics experiments. 
Urine samples were prepared according to the 
procedure described by Marques et al. [159]. 
Samples were analyzed by HPLC/Orbitrap 
according to the method described by 
Fernandes et al. [160].  MS data was uploaded 
into XCMS Online and was processed as a multi-
group experiment using the default 
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HPLC/Orbitrap parameters in negative mode 
(fecal samples) or positive mode (urine 
samples) [161]. Isotopes and adducts were 
annotated using CAMERA and arranged into 
feature groups. Metabolite features were 
selected to assess the differences between the 
fecal and urine samples of C, C+BE, HF and 
HF+BE groups. Tryptophan, kynurenine and 
kynurenic acid (MilliporeSigma, St. Louis, MO, 
USA) were used as standards.  
 
Statistical analysis 
Two-way ANOVA was used to determine the 
main effects of diet (CDe vs HF diet), BE 
supplementation (No BE vs BE) and their 
interaction. In XCMS online, one-way ANOVA 
followed by a post hoc multi comparison test 
was used in multi group experiment. To 
compare the differences between two groups, 
t-test was used. Correlation between variables 
was established using Spearman’s correlation 
test. Statistical analyses were performed using 
SPSS Statistics 23 (IBM, USA) software. 
Differences were considered statistically 
significant when p< 0.05. Principal component 
analysis (PCoA) was performed in R 3.0.2 (The R 
Foundation, New Zealand) with the RStudio 
0.97.310 package. Heatmaps were elaborated 
using CIMminer platform 
(https://discover.nci.nih.gov/cimminer/home.d
o).   
 
RESULTS 
 
Blackberry anthocyanins modulate gut-
microbiota composition and counteract HF 
diet-induced dysbiosis 
We compared the gut microbial community of 
Wistar rats fed either with standard (C) or high-
fat (HF) diet and supplemented with blackberry 
anthocyanin extract (BE) by sequencing the V3-
V4 regions of the 16S rRNA gene.  
The gut microbiota of the animals was 
dominantly constituted by five phyla: 
Firmicutes, Bacteroidetes, Actinobacteria, 
Verrucomicrobia and Proteobacteria (Fig. 1A). 
Firmicutes to Bacteroidetes ratio was not 
significantly different among groups (p>0.05) 
(Fig. 1B).  Despite no differences were observed 
at phylum level, at genus level, major 
differences were noted.   
Results illustrated in Fig. 2A indicate the genus 
level distribution for the 4 diet groups. After 17 
weeks of HF feeding, the gut microbiota of HF 
fed animals was largely altered comparatively 
to the gut microbiota of C animals. Notably, 
bacteria belonging to the Firmicutes phylum 
such as Rumminococcus, Blautia, 
Erysipelatoclostridium, Streptococcus and 
Parasporobacterium were more abundant in HF 
fed animals (p<0.05), whereas 
Lachnoclostridium, Pseudoflavonifractor, 
Oscillibacter and Anaerostipes (also Firmicutes) 
were more abundant in the animals of C group 
(p<0.05) (Fig. 2A). In addition, HF diet 
decreased the abundance of Akkermansia, 
Prevotella and Paraeggerthella (p<0.05), 
whereas increased the abundance of 
Desulfovibrio, Rothia and Enterohabdus 
(p<0.05) (Fig. 2A).  
BE instigated several modifications in the gut 
microbiota composition of the animals. 
Specifically, BE increased Pseudoflavonifractor 
when the animals were fed with C diet whereas 
increased Oscillobacter independently of the 
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diet fat content (p<0.05) (Fig. 2A). Moreover, 
BE struggled to recover the gut microbiota’s 
diversity when the animals were challenged 
with HF diet, as indicated by Shannon’s richness 
index (Fig. 2C). 
To reduce the number of variables, a principal 
coordinate analysis (PCoA) was performed. The 
gut microbiota communities from the four 
different groups (C, BE, HF and HFBE) were 
grouped into four different clusters (Fig. 2C). HF 
fed rats had a distinct gut microbiota that 
clustered separately from C and BE rats. 
Nevertheless, the gut microbiota communities 
of the HF+BE animals were also differentiated 
from those of HF rats (Fig. 2C). The reduction of 
Rumminococcus and the prevalence of 
Sporobacter were the main features that 
justified the segregation of HF+BE from HF 
group (Fig. 2D). 
In summary, our data indicate that HF feeding 
strongly affect the composition of the gut 
microbiota and that BE can counteract some of 
the features of HF-diet induced dysbiosis.  
 
Changes in gut bacterial genera prompted by 
blackberry anthocyanins are correlated with 
some of their anti-neuroinflammatory 
properties  
After characterizing the gut microbiota of the 
animals supplemented with BE, we sought to 
investigate if the protection against 
neuroinflammation, previously evaluated by 
our group, was associated with the changes 
observed in the gut bacterial genera of these 
animals.  
In a previous work, we showed that BE 
consumption decreased TCK-1 expression in 
rat’s hippocampus whereas fractalkine 
expression increased [151]. Here, we found 
that TCK-1 was negatively correlated with 
Pseudoflavonifractor and Sporobacter when the 
animals were fed with C and HF diet, 
respectively (p<0.05) (Fig. 3A and 3B). 
Interestingly, these bacterial genera were those 
increased by BE in C and HF diet groups, 
respectively (Fig. 2A). On the other hand, it was 
interesting to note that fractalkine, a 
chemokine extremely important in the 
crosstalk between neurons and microglia, was 
not correlated with any bacterial genus despite 
being upregulated in BE supplemented rat’s 
hippocampus (Fig. 3A and 3B). 
 
Blackberry anthocyanins modulate CNS 
inflammation via the microbial metabolites of 
tryptophan  
As a component of the gram-negative bacteria 
and a trigger of the inflammatory response, 
lipopolysaccharide (LPS) was measured in the 
fecal samples of all animals. Although fecal LPS 
levels were not statistically different among 
groups (p> 0.05), a noticeable increase in LPS 
levels was observed in the fecal samples of the 
animals of HF diet group (Fig. 4). On the other 
hand, in HF+BE animals, fecal LPS seemed to 
return to control levels, probably as a reflection 
of the gut microbiota modifications that BE 
brought about in HF fed animals (Fig. 4).  
The LC/MS analysis revealed the existence of 
additional compounds in the animals' fecal 
samples. Twenty-six compounds with a 
maximum intensity above 1 000 000 were 
significantly altered between samples (p< 0.01) 
(Fig. 5). Tryptophan (one of the identified 
metabolites) was decreased in the groups 
supplemented with BE (p< 0.05, Fig. 5). 
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Interestingly, fecal concentrations of 
tryptophan were positively correlated with 
TCK-1 expression in the hippocampus (r = 
0.733, p< 0.05). Changes in the gut bacterial 
genera prompted by BE could have altered host 
tryptophan metabolism. To verify this 
assumption, tryptophan and tryptophan 
metabolites (kynurenine and kynurenic acid) 
were searched in the urine of all animals. 
Tryptophan and kynurenic acid (Figure 6) were 
increased in the urine of the animals fed with 
HF diet and supplemented with BE (p< 0.05), 
while kynurenine levels remained unchanged. 
On the contrary, this was not observed in the 
animals of C+BE group.  
 
DISCUSSION 
 
The present findings demonstrate for the first 
time that blackberry anthocyanins are able to 
counteract HF diet-induced dysbiosis. In 
addition, we demonstrate that anthocyanin-
induced changes in the gut microbiota 
composition are related with their anti-
neuroinflammatory properties. Finally, we 
propose that anthocyanins are able to 
counteract diet-induced neuroinflammation 
through the stimulation of tryptophan 
metabolism along the kynurenine pathway.  
A number of studies have shown that mental 
illness may have origins in the gut [95, 162, 
163]. Indeed, compelled by the study of Bruce-
Keller et al., we have already proposed that HF 
diet-induced dysbiosis could be the trigger of 
neuroinflammation, a common hallmark of 
neuropsychiatry disorders [147].  
Besides changing the gut microbiota 
composition abruptly (HF-diet induced 
dysbiosis), HF diet can also increase intestinal 
permeability, facilitating the passage of LPS into 
the circulation [61]. In addition, LPS transport 
from the intestine towards target tissues can 
also be enabled by the chylomicrons 
synthesized in response to fat feeding [57].  
Once in circulation, LPS may activate 
CD14/TLR4 signaling in target tissues, including 
the brain. LPS can also disrupt the blood-brain 
barrier and induce neuroinflammation [164]. 
Nevertheless, LPS plasma levels of the animals 
fed with HF diet were not altered, probably 
because the animals were fasted before 
sacrifice [165]. However, the propensity for 
increased fecal LPS levels may reflect the 
alterations in the gut microbiota composition 
brought about by HF diet and might be 
indicative of higher amounts of LPS in plasma. 
On the other hand, increased fecal LPS levels 
may activate dendritic cells within the intestinal 
barrier, increasing the production of cytokines 
and, thus contributing to peripheral and 
systemic inflammation [166]. In the present 
study, we evaluated whether anthocyanins 
were able to counteract these effects of HF 
diet.  
Anthocyanins bioavailability was initially 
considered to be low. This was due to some 
major drawbacks of the former studies in the 
field which, among other issues, have 
overlooked anthocyanin metabolites produced 
by the gut microbiota [167]. In fact, 
anthocyanins are extensively metabolized by 
the gut bacteria and these compounds can 
predominate during several days in the 
organism given the enterohepatic recirculation 
[137, 167]. On the other hand, at the same time 
they are utilized by these microorganisms, 
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anthocyanins can selectively stimulate the 
growth of some bacterial groups [137].  Hidalgo 
et al. analyzed the effects of anthocyanins upon 
gut microbiota composition by real-time PCR, 
using batch culture fermentations and they 
have shown that anthocyanins significantly 
enhanced the growth of Lactobacillus-
Enterococcus spp and Bifidobacterium spp 
[138]. Here, we showed for the first time a 
complete picture of the modulation of gut 
microbial genera by blackberry anthocyanins, in 
an animal model. Anthocyanins were able to 
counteract some of the features of HF-diet 
induced dysbiosis, including fecal LPS levels 
and, in the context of a standard diet, 
anthocyanins increased Pseudoflavonifractor. 
Pseudoflavonifractor was found to be 
decreased in long-term proton pump inhibitor 
users which utilization is associated to an 
increased risk of Clostridium difficile infection 
[168]. Besides, in a different study, 
Pseudoflavonifractor increased the success of 
obese patients in losing weight consistently 
[169]. 
After confirming that anthocyanins are able to 
modulate gut microbiota composition and 
counteract HF-diet induced dysbiosis, we 
demonstrated that the anthocyanin-induced 
changes in the gut microbiota profile were 
correlated with their anti-neuroinflammatory 
properties previously assessed on the 
hippocampus of the same animals. This 
reinforces the idea that protection against 
neuroinflammation can be due to gut 
microbiota modifications. 
Besides LPS, other pathways may be involved in 
the bilateral communication between the gut 
and the brain [170]. Since tryptophan was 
decreased in the fecal samples of the animals 
supplemented with BE, we decided to explore 
the metabolic pathway of tryptophan.  As a 
precursor of serotonin, kynurenine and 
downstream metabolites of the kynurenine 
pathway, changes in the supply and availability 
of this essential amino acid has many 
implications for CNS functioning [104]. The 
dietary protein intake was the same in the 
groups supplemented with BE compared to the 
respective controls. Therefore, if tryptophan 
was decreased in the fecal samples of the 
animals supplemented with BE, it could be 
because BE was stimulating either the microbial 
catabolism of tryptophan or the host 
tryptophan metabolism. Around 90% of 
tryptophan is metabolized along the 
kynurenine pathway [102]. In this regard, we 
looked for kynurenine and kynurenic acid 
(tryptophan metabolites produced along this 
pathway) in the urine of all animals. 
Interestingly, we found that tryptophan and 
kynurenic acid were increased in the HF+BE 
group. This result suggests that tryptophan is 
being converted in kynurenine and, in turn, 
kynurenine is being converted into kynurenic 
acid. Kynurenic acid acts as an antagonist of the 
excitatory amino acid receptors and has been 
implicated in major psychiatric diseases [171]. 
Alterations in the gut microbial composition 
might result in changes in serum and urine 
kynurenic acid levels and could thus modify 
CNS excitation and behavior [170]. Some 
studies have also report the anti-inflammatory 
properties of kynurenic acid [172, 173].  
The increased production in kynurenic acid 
could explain, at least in part, the anti-
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neuroinflammatory properties of anthocyanins, 
especially in the context of HF diet.  
Nonetheless, tryptophan could be also being 
used  for the serotonin synthesis in the gut  
[174] or for indole production by gut bacteria 
which has been shown to increase intestinal 
barrier integrity [175]. 
However, the direct role of anthocyanins in the 
brain may not be ruled out. Anthocyanin 
metabolites can accumulate in the brain and 
exert their effects directly, including the 
stimulation of fractalkine secretion [150, 176]. 
In conclusion, anthocyanins alter host 
tryptophan metabolism, generating 
metabolites responsible for the control of CNS 
inflammation which may constitute another 
mechanism behind their anti-
neuroinflammatory properties. Anthocyanins 
may act, therefore, as mediators of the 
microbiota-gut-brain axis, allowing the control 
of neuroinflammation by gut microbiota 
modulation. 
These results strongly suggest that dietary 
manipulation of the gut microbiota by 
anthocyanins could attenuate the neurologic 
complications of obesity. Anthocyanins emerge, 
therefore, as a new class of psychobiotics.  
Lastly, these preclinical studies have prompted 
interest in whether targeting the gut 
microbiota with anthocyanins might be a viable 
strategy to influence tryptophan availability for 
kynurenine metabolism and 
neuroinflammatory control within CNS.  
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Figure 1 - (A) Major bacterial phyla in the gut microbiota of rats after 17 weeks of high-fat (HF) feeding 
and anthocyanins-rich blackberry extract (BE) supplementation. Bars represent the average of each 
phylum relative abundance in the 4 different diet groups. Each phylum is represented by a different color 
(n=5-6 rats per group). (B) Firmicutes to Bacteroidetes ratio among groups. This ratio was calculated by 
dividing the relative abundance of Firmicutes by the relative abundance of Bacteroidetes. Values are 
expressed as mean ± SEM (n=5-6 rats per group). 
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Figure 2 - Gut microbiota composition at the genus level among groups (n=5-6 per group). (A) Relative 
abundance of gut bacterial genera. Bars represent the average of each genus relative abundance in the 4 
different diet groups. Each genus is represented by a different color. (B) Shannon’s diversity index among 
groups. Values are expressed as mean ± SEM. (C) Gut bacterial genera were clustered using principal 
component analysis (PCoA). Results are plotted according to the first two principle components, which 
explain 36.8% (PC1) and 25.7% (PC2) of the variation in gut microbial composition (at genus level) 
between samples. Each point represents one sample and each diet group is denoted by a different color. 
Circles combine samples from the same diet group by their respective 95% confidence interval ellipse. 
(D) Heatmap and hierarchical clustering of the relative abundance of gut bacterial genera. Rows 
correspond to operational taxonomic units (OTUs) and columns represent the animals of the 4 different 
diet groups.  
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Figure 3 - Heatmap of Spearman’s correlation test between gut bacterial genera and neuroinflammatory 
markers measured in hippocampus, (A) in the animals fed with standard diet (C and BE groups) and (B) in 
high-fat fed animals (HF and HFBE groups). Green color indicates a positive correlation while red color 
indicates a negative correlation. Squared cells represent correlations with statistical significance (p< 0.05).  
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Figure 4 - Fecal LPS concentrations. Values are expressed as mean ± SEM (n=5-6 rats per group). 
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Figure 5 - (A) Metabolite features whose level varies significantly (p< 0.01) across groups are projected on 
the cloud plot depending on their retention time (x-axis) and m/z (y-axis). Statistical significance (p-value) 
is represented by the bubble’s color intensity. The size of the bubble denotes feature intensity (only 
features with maximum intensity above 1 000 000 are displayed). Feature assignments (p-value, m/z, RT) 
are displayed in a pop-up window for the identified metabolite tryptophan. (B) Extracted ion 
chromatogram (EIC) and (C) Boxplot of tryptophan. *p<0.05 vs respective control. 
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Figure 6 - (A) Tryptophan and tryptophan metabolites searched in the urine of the animals of all groups. 
(B) Boxplot of tryptophan and (C) Boxplot of kynurenic acid.  *p<0.05 vs respective control. 
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Concluding Remarks 
 
When it comes to our microbes, we are never alone. The human gut households trillions of 
microorganisms that have been evolving with us for millions of years [154]. On account of the 
technological advances, the scientific community have been exploring the dynamics of such 
complex ecosystem. The role these microorganisms play in our health is still a mystery but 
emerging evidence suggest that gut microbiota dysbiosis is implicated in a number of diseases 
ranging from localized gastrointestinal disorders to autoimmune, hepatic, respiratory, 
cardiovascular, oncologic, metabolic, neurologic and psychiatric diseases [155].  
The incidence of these diseases, specially obesity and obesity associated metabolic disorders has 
substantially increased during the past two centuries. This period encompasses only a limited 
number of human generations, which makes obesity epidemic unlikely to be explained by 
genetic factors alone. On the other hand, the environmental and behavioral changes (including 
dietary modifications and exposure to xenobiotics), largely adopted by post-industrial revolution 
societies, are probably related to the increasing incidence of these inflammatory and metabolic 
diseases [122, 156]. Nonetheless, both human and microbial genomes have been subject to 
these rapid environmental pressures. Therefore, another gene pool - the gut microbiome - has 
to be considered when evaluating the impact of such environmental factors on human health.  
Humans and their microbiome form a composite organism, the so-called “holobiont” [157, 158]. 
The hologenome theory of evolution proposes that natural selection acts not on the individual 
organism but on the “holobiont” [159]. Thus, when a “holobiont” is challenged by dramatic 
changes, such as altered diet, reduced physical activity or drugs, it employs adaptive 
mechanisms in the form of reshuffling/balancing its microbiome [159]. The significantly shorter 
generation time of microorganisms, make the microbiome responsive to rapid evolutionary 
changes on a much shorter timescale than the host genome [122]. The human microbiome is 
highly mutable and its functional capacity is dynamic [160]. Nevertheless, every time it changes 
to adapt to new environmental conditions, some functions might get lost, which can be 
detrimental for human health. 
The compilation of studies unveiled in this thesis intended to explore the effects of a particular 
class of dietary compounds (anthocyanins) on the gut microbiota composition. The 
bioavailability of anthocyanins is considered to be low, therefore, it is expected that high 
amounts of these compounds reach the colon after consumption of anthocyanins-rich foods. 
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The main aim of this work was to verify whether they could prevent the dysbiosis associated 
with obesity and the consequent metabolic and neurologic disorders that can emerge from such 
a disrupted microbiome. To obtain an animal model of obesity and its associated metabolic 
disorders, in which the effects of anthocyanins could be studied, our primary approach was to 
use an high-fat and high-sucrose diet (45 % and 17 % of energy, respectively) to induce obesity in 
rats (Chapter II-A, Chapter II-B, Chapter II-D). A genetic animal model of obesity was not used 
since, as discussed above, genetics are probably not the major driving force of obesity 
epidemics.  
The high-fat and high-sucrose diet (HF diet) was carefully chosen to adequately mimic the 
modern dietary pattern (Western diet) adopted by post-industrial revolution societies [161]. This 
type of diet is able to induce obesity and metabolic disorders in rodents resembling human 
metabolic syndrome [161, 162]. Moreover, HF diet abruptly change the composition of the gut 
microbiota and these changes seem to be associated with the development of obesity and its 
related metabolic complications [163-168].  
Gut microbiota is probably indispensable for obesity development, as germ-free animals are 
resistant to HF diet-induced obesity [33]. On the other hand, it is well established that a 
disrupted microbiome, either from HF diet-induced obesity rodents, obese individuals (that 
usually have a diet rich in fat, sugar and food additives) or from ob/ob animals (that continuously 
have a sense of starvation and exhibit hyperphagia), initiates obesity after transplantation to 
germ-free animals [25, 169, 170]. Therefore, it is important to characterize these diet-induced 
changes on the gut microbiota composition since they might be responsible for the onset of 
obesity and metabolic disorders. 
Wistar and Sprague-Dawley are the main Rat strains used as HF diet-induced obesity models 
[171-174]. Nevertheless, a suitable comparison between these two Rat strains as HF-diet 
induced obesity models was not available in the literature. Furthermore, the effects of HF diet 
upon the gut microbiota of these animals were not previously characterized. Therefore, in 
Chapter II-A, Wistar and Sprague-Dawley rats were studied in parallel to determine the most 
appropriate model where the effect of anthocyanins could be investigated (Chapter II-D). 
As discussed in Chapter II-A, both strains can be used as models of HF diet-induced obesity, 
although Wistar rats seemed to be particularly predisposed to HF diet-induced obesity and 
metabolic disorders [175]. The gut microbiota composition of the two Rat strains differed in 
some of the bacterial genera analyzed which can explain different metabolic responses to HF 
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diet [175]. As previously reported, host genetics may influence the gut microbiota composition 
which may predict, in turn, the effects of dietary interventions on host metabolic parameters 
[176-178]. 
In Chapter II-B, Wistar rats with high-fat diet induced obesity were further characterized 
concerning intestinal injury and inflammation [179].  
The intestinal epithelium is a highly regulated physical barrier that secretes several compounds 
such as mucus and antimicrobial peptides which, together, act as front lines of defense 
protecting the host against bacterial translocation [180]. Recently, it has been hypothesized that 
gut barrier dysfunction in obesity leads to the passage of microbial components into circulation, 
which drives systemic inflammation [181]. Moreover, HF diets can compromise gut mucosal 
integrity and, therefore, contribute to metabolic endotoxemia [182-186]. Herein (Chapter II-B), 
intestinal fatty-acid binding protein (I-FABP) and glucagon-like peptide-2 (GLP-2) were evaluated 
as putative biomarkers of intestinal permeability in the context of HF-diet induced obesity [179]. 
Although I-FABP ended up not being a good biomarker of intestinal permeability, GLP-2 was 
surprisingly increased in the plasma of HF diet fed animals and were positively correlated with 
systemic inflammatory markers [94]. 
As discussed in that chapter, the inflammatory state driven by gut microbiota modifications after 
HF-diet feeding might have increased GLP-2 production in order to improve the mucosal barrier 
integrity and, therefore, blunt the inflammatory stress [179]. Accordingly, a very recent report 
has shown that the L cell is as a key mucosal sensor of gut injury, which responds to mucosal 
damage by secretion of glucagon-like peptides which, in turn, promote restoration of mucosal 
integrity and attenuation of inflammation [187]. Therefore, GLP-2 may be used as a biomarker of 
intestinal permeability to anticipate the progression of obesity-associated metabolic disorders. 
Apart from being implicated in the onset and development of metabolic diseases, the HF-diet 
disrupted microbiota may also be implicated in several neurologic conditions involving 
inflammation. The idea that HF diet-induced dysbiosis is a rational cause of obesity-related 
neuroinflammation was significantly reinforced in Chapter II-C, after the publication of Bruce 
Keller et al [188, 189]. These authors have demonstrated that mice receiving an obese-type 
microbiota exhibited increased neuroinflammation together with significant disruptions in 
exploratory, cognitive and stereotypical behaviors (increased anxiety and decreased memory) 
[188].  
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Given the immunomodulatory properties of the gut microbiota, immune cell pathways have 
been highlighted as important mechanisms mediating microbial modulation of brain function 
and behavior [190]. Intestinal microbes modulate the maturation and function of microglia and 
astrocytes within the CNS while they also influence the activation of peripheral immune cells 
that regulate responses to neuroinflammation, brain injury and neurogenesis [190]. 
Consequently, germ-free mice which are raised under sterile conditions exhibit substantial 
alterations in behavior (reduced anxiety-like behavior, reduced social behavior, hyperactivity) 
and display learning and memory deficits compared to conventional raised mice [191-194] .  
The activation of these immune pathways in the host result from the recognition of microbial 
derived products via TLRs. TLRs are the most well characterized family of pattern recognition 
receptors and are expressed not only on innate immune cells but also on CNS cell populations, 
including neurons and glial cells [195]. Thus, TLR ligands derived from the intestinal microbiota 
(e.g. LPS) may be capable to directly trigger innate immune pathways to affect CNS function 
[196, 197].  
In HF-diet induced obesity mice, fecal LPS levels are increased (as a result of HF-diet induced 
dysbiosis) along with systemic LPS levels (LPS is absorbed together with fat) [63]. Moreover, the 
increased intestinal permeability observed in these animals intensifies the passage of TLR ligands 
from the gut microbiota to the systemic circulation [66]. Thenceforward, TLR ligands may 
activate microglia in the brain and, consequently, induce neuroinflammation [198, 199]. 
Accordingly, results from Chapter II-A, II-B and II-C show that Wistar rats with HF-diet induced 
obesity exhibited gut microbiota dysbiosis, increased fecal LPS concentrations, increased 
intestinal permeability (assessed by GLP-2) and neuroinflammation [148, 175, 179, 189]. 
Altogether, these data highlight the importance of targeting HF-diet induced dysbiosis in the 
treatment of neuropsychiatry disorders. 
Besides being tangled in anxiety and depression (neuropsychiatry disorders whose risk is 
tremendously increased by obesity), neuroinflammation plays a prominent role in the 
progression of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease [200, 
201]. As population gets older, the incidence of neurodegenerative diseases, become 
increasingly more prevalent and new therapeutic strategies are warranted [202]. Recent 
evidence have shown that neurodegenerative alterations in Parkinson’s disease are 
accompanied by gastrointestinal symptoms that may precede or follow CNS impairment 
[100]. Consequently, gut microbiota modifications may also constitute a promising therapeutic 
option for neurodegenerative diseases. 
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Targeting the gut microbiota with prebiotics might be a good strategy to nurture a beneficial 
microbiome and prevent dysbiosis-associated diseases [95, 203].  
The most studied prebiotics are non-digestible carbohydrates to fulfill the criteria of previous 
prebiotic definition [204]. However, the definition of prebiotics has been modified to “a 
substrate that is selectively utilized by host microorganisms conferring a health benefit” [205]. 
Other substances, beyond carbohydrates, might fit the updated definition if convincing evidence 
demonstrates their health benefits. Compounds such as polyphenols, namely anthocyanins, may 
be considered prebiotics, according to this new definition. 
Anthocyanins turn out to be particularly relevant since their bioavailability is considered to be 
low. Therefore, after consumption of anthocyanin-rich foods, it is expected that high amounts of 
anthocyanins reach the intestine to modulate bacterial growth at the same time they are 
metabolized by the existing bacteria.   
In Chapter II-D, the effects of anthocyanins on gut microbiota were evaluated using the HF-diet 
induced obesity model characterized in Chapters II-A, II-B and II-C. The modifications in the gut 
microbiota composition brought about by anthocyanins were not sufficient to prevent the onset 
and development of obesity and metabolic diseases but, somehow, attenuated the detrimental 
effects of neuroinflammation in a high-fat challenged brain [148, 206].  
Moreover, in the same chapter, an attempt to unravel the mechanisms behind the 
neuroprotective effects of anthocyanins was conducted. Despite some modifications in the gut 
microbiota composition, the fecal LPS concentrations were not significantly decreased by 
anthocyanins nor GLP-2 plasma levels (data not shown), which indicate that anthocyanins did 
not preclude gut barrier dysfunction. Nevertheless, anthocyanins may interfere in other 
mechanisms by which the gut can communicate with the brain.  
One of these mechanisms is related to the ability of intestinal bacteria to modulate the host 
metabolome. Circulating metabolites can enter the CNS and directly affect neuroactivity [207]. 
Conversely, particular metabolites can regulate the function of peripheral immune cells which 
can then influence brain function [208]. 
Results from this chapter revealed that the alterations in gut microbial composition brought 
about by anthocyanins resulted in changes in the levels of tryptophan and kynurenic acid which 
has been implicated in CNS inflammation, excitation and behavior (Figure 5). 
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Psychobiotics were previously defined as live bacteria which, when ingested, confer mental 
health benefits through interactions with commensal gut bacteria [209]. Recently, this definition 
was expanded to encompass prebiotics [210]. Therefore, according to the results present in this 
thesis, anthocyanins might constitute a new class of psychobiotics.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 - Mechanisms behind the neuroprotective effects of anthocyanins, in the context of HF-
diet induced obesity. Anthocyanins act directly in the brain increasing the expression of 
fractalkine, a chemokine extremely important in the crosstalk between neurons and microglia 
during synaptic plasticity [148]. On the other hand, anthocyanins modulate the gut microbiota 
composition, increasing the bacterial genus Sporobacter and alter host tryptophan metabolism. 
The amount of tryptophan available is decreased by anthocyanins to undergo the kynurenine 
pathway and originate kynurenic acid, a metabolite whose neuroprotective actions were 
recently identified [211, 212]. Through these routes, anthocyanins counteract the HF-diet 
induced neuroinflammation and may attenuate the neurological complications of obesity as well 
as neurodegenerative diseases.  Anthocyanins might constitute, therefore, a new class of 
psychobiotics. TCK-1, thymus chemokine-1. 
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Future Perspectives 
 
The preclinical studies presented in Chapter II require further validation in humans. Clinical trials 
are necessary to confirm the effects of anthocyanins on the gut microbiota and whether they 
can be a useful tool in the management of neuropsychiatry and neurodegenerative disorders.  
The first thing to address in humans is the bioavailability of these compounds. The bioavailability 
of anthocyanins is considered to be low but in fact, anthocyanins are rather extensively 
metabolized. In Chapter III, the analysis of plasma and urine samples of healthy volunteers after 
the ingestion of a blackberry puree revealed that the plasma concentration of anthocyanins’ 
parent structure (the one that naturally occurs in fruits and is actually consumed) is almost ten 
times lower than the newly formed metabolites [213]. Nonetheless, this discrepancy might be 
even bigger if the metabolites that are produced by the gut microbiota were considered. Thus, 
the bioavailability of anthocyanins might not be that low. Given the enterohepatic recirculation, 
these compounds may prevail in the human body for several days [214]. Moreover, they can 
accumulate in several organs where they can exert their effects [215].  
Another interesting point addressed in Chapter III was the difference between normal weight 
and obese individuals regarding the metabolism of anthocyanins [213]. The disrupted gut 
microbiota as well as the generalized metabolic dysfunction unveiled by obese individuals may 
be behind the variability observed between these two groups. Obesity may comprise the 
metabolism of these compounds which deserves special consideration since obese individuals 
might be the ones who would benefit the most from anthocyanins intervention.  
The first steps in the human studies were already undertaken in Chapter III of this thesis. 
However, quoting George Bernard Shaw, “science never solves a problem without creating ten 
more”. 
Which metabolites are originated from the microbial metabolism of anthocyanins? Are they 
more bioactive than the parent compounds? How they interfere with host tryptophan 
metabolism? Do they contribute to the prevention of neuroinflammation? These are questions 
that still need to be unraveled and will inspire future clinical trials. 
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